Scarica l'app Stockscreener
45.96
2.20%
1.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com
Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus
Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus
A first FDA-approved eye biosimilar returns to U.S. sales - Stock Titan
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow - Business Wire
A Look at Harrow Inc (HROW) After 3.2% Gain -- GF Value $42.31 v - GuruFocus
Cantor Fitzgerald Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Harrow, Inc. Actuals & Estimates (NASDAQ:HROW) - TradingView
HROW Forecast — Price Target — Prediction for 2027 - TradingView
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices - simplywall.st
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 - Insider Monkey
Form 4 Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant - Stock Titan
Harrow (HROW) director granted 5,248 restricted stock units as compensation - Stock Titan
Form 8K Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
Harrow elects directors and approves executive compensation at annual meeting - Investing.com
Harrow, Inc. (NASDAQ: HROW) 2026 Annual Meeting Results: Shareholder Votes and Key Decisions from Form 8-K Filing – Minichart - Minichart
Harrow (HROW) investors back all 2026 director, pay and auditor proposals - Stock Titan
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$Harrow (HROW.US)$ i shouldve put more in - Moomoo
Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing - simplywall.st
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Insider Monkey
Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy? - Yahoo Finance
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Return on invested capital % of Harrow, Inc. – FWB:3IP - TradingView
Harrow Inc. Q1 2026 Earnings: Significant EPS Miss Triggers Stock DeclineBook Value Growth - newsline.com
HARROW INC (HROW) Stock Chart - ChartMill
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target? - Insider Monkey
0.15%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):